Hagop Kantarjian, MD, on CAR T Cells in Relapsed/Refractory ALL

2014 ASH Annual Meeting

Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 380, “T Cells Engineered with a Chimeric Antigen Receptor (CAR)-Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children With Relapsed, Refractory ALL,” presented by Stephan A. Grupp, MD, PhD; abstract 381, “Intent-to-Treat Results of a Phase I Trial of CD19 Chimeric Antigen Receptor Engineered T Cells Using a Consistent Treatment Regimen Reveals a 67% Complete Response Rate in Relapsed, Refractory Acute Lymphoblastic Leukemia,” presented by Daniel W. Lee III, MD; and abstract 382, “CD19-Targeted 19-28z CAR Modified Autologous T Cells Induce High Rates of Complete Remission and Durable Responses in Adult Patients With Relapsed, Refractory B-Cell ALL,” presented by Jae H. Park, MD.

Bertrand Coiffier, MD, PhD, on the Phase III LyMa Trial

Bertrand Coiffier, MD, PhD, of Centre Hospitalier Lyon-Sud, offers his thoughts on abstract 146, “Rituximab Maintenance vs Wait and Watch After Four Courses of R-DHAP Followed By Autologous Stem Cell Transplantation in Previously Untreated Young Patients With Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective LyMa Trial, a Lysa Study,” presented by Steven Le Gouill, MD, PhD.

Lymphoma

Laurie Sehn, MD

Laurie Sehn, MD, on Brentuximab Vedotin in Diffuse Large B-Cell Lymphoma With Undetectable CD30

Laurie Sehn, MD, of the BC Cancer Agency, on abstract 629, “Brentuximab Vedotin Monotherapy in Diffuse Large B-Cell Lymphoma Patients With Undetectable CD30: Preliminary Results From a Phase II Study.”

Lymphoma

James O. Armitage, MD, FACP, FRCP, and Bertrand Coiffier, MD, PhD

James O. Armitage, MD, FACP, FRCP, and Bertrand Coiffier, MD, PhD, on Managing Lymphoma: The French Perspective

James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Bertrand Coiffier, MD, PhD, of the Centre Hospitalier Lyon-Sud discuss three French studies on rituximab maintenance vs wait and watch after R-DHAP in mantle cell lymphoma; R-CHOP with or without radiotherapy in diffuse large B-cell lymphoma; and romidepsin and CHOP in peripheral T-cell lymphoma.

Hematologic Malignancies

Keith McCrae, MD

Keith McCrae, MD, on Managing Heparin-Induced Thrombocytopenia

Keith McCrae, MD, of the Cleveland Clinic, offers his thoughts on abstract 4848, “Implementation of a Heparin-Induced Thrombocytopenia Management Program Reduces the Cost of Diagnostic Testing and Pharmacologic Treatment in an Academic Medical Center,” presented by Caroline Dupre Vaughn, RN.

Leukemia

Lymphoma

Matthew Lunning, DO

Matthew Lunning, DO, on Ublituximab Plus TGR-1202 in Lymphoma

Matthew Lunning, DO, of the University of Nebraska Medical Center, on abstract 801, “Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with TGR-1202, a Next-Generation Once Daily PI3kδ Inhibitor, Demonstrates Activity in Heavily Pretreated and High-Risk Chronic Lymphocytic Leukemia and B-Cell Lymphoma.”

Jun

Today In Oncology

Hagop Kantarjian, MD, on CAR T Cells in Relapsed/Refractory ALL

Related Videos

Bertrand Coiffier, MD, PhD, on the Phase III LyMa Trial

Laurie Sehn, MD, on Brentuximab Vedotin in Diffuse Large B-Cell Lymphoma With Undetectable CD30

James O. Armitage, MD, FACP, FRCP, and Bertrand Coiffier, MD, PhD, on Managing Lymphoma: The French Perspective

Keith McCrae, MD, on Managing Heparin-Induced Thrombocytopenia

Matthew Lunning, DO, on Ublituximab Plus TGR-1202 in Lymphoma

Study Finds About One in Six Chemotherapy Drugs in Sub-Saharan Africa Fails Quality Tests

Partial-Breast Radiotherapy After Breast-Conserving Surgery: 10-Year Outcomes

Neoadjuvant Durvalumab Plus Chemotherapy for High-Risk Upper Tract Urothelial Carcinoma

Patterns of ICI Use and Survival Outcomes in Metastatic Colorectal Cancer

Genitourinary Oncology Highlights: Treatment Advances in Renal Cell, Bladder, Urothelial, and Prostate Cancers